Download PDF
Fortschr Neurol Psychiatr 2012; 80(9): 492-500
DOI: 10.1055/s-0031-1299349
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Atypische Parkinson-Syndrome – Aktuelles aus Diagnostik und Therapie

Atypical Parkinson Syndromes – Recent Advances in Diagnosis and Therapy
S. Duerr
,
G. K. Wenning
,
K. Seppi
,
W. Poewe
Further Information

Publication History

Publication Date:
28 March 2012 (online)

    Permissions and Reprints

Zusammenfassung

Der Begriff „atypische Parkinson-Syndrome“ umfasst die Multisystematrophie (MSA), die progressive supranukleäre Blickparese (PSP) und das kortikobasale Syndrom (CBS). Eine Differenzierung dieser verschiedenen Krankheitsentitäten von der „klassischen“ Parkinson-Krankheit stellt weiterhin selbst für den Spezialisten eine Herausforderung dar, da abhängig von der genauen Diagnose große Unterschiede sowohl im Ansprechen auf die Therapie als auch deren Prognose bestehen. Ziel dieser Arbeit soll sein, zum einen eine Übersicht zu den aktuellen Diagnosekriterien und pragmatisch-therapeutischen Ansätzen zu geben als auch auf rezente Ergebnisse aus klinischen Studien und experimenteller Forschung einzugehen.

Abstract

The term “atypical Parkinson syndromes” usually encompasses the following diseases: multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The differential diagnosis is still a challenge even for a movement disorders specialist, not least because of the distinct therapeutic approaches and disease prognosis. The aim of this review is to provide an overview of current diagnostic criteria and therapeutic approaches and to cite recent findings from clinical and experimental studies.

Schlüsselwörter

atypische Parkinson-Syndrome - Diagnose - Therapie

Key words

atypical Parkinson syndromes - diagnosis - therapy
 

  • Literatur

  • 1 Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of neurology, neurosurgery, and psychiatry 1992; 55: 181-184
    CrossrefPubMedGoogle Scholar
  • 2 Hughes AJ, Daniel SE, Ben-Shlomo Y et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870
    CrossrefPubMedGoogle Scholar
  • 3 Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-1775
    CrossrefPubMedGoogle Scholar
  • 4 Stefanova N, Reindl M, Neumann M et al. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 2007; 22: 2196-2203
    CrossrefPubMedGoogle Scholar
  • 5 Scholz SW, Houlden H, Schulte C et al. SNCA variants are associated with increased risk for multiple system atrophy. Annals of neurology 2009; 65: 610-614
    CrossrefPubMedGoogle Scholar
  • 6 Lee JY, Lee WW, Kim JS et al. Perverted head-shaking and positional downbeat nystagmus in patients with multiple system atrophy. Mov Disord 2009; 24: 1290-1295
    CrossrefPubMedGoogle Scholar
  • 7 Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676
    CrossrefPubMedGoogle Scholar
  • 8 Lipp A, Sandroni P, Ahlskog JE et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66: 742-750
    CrossrefPubMedGoogle Scholar
  • 9 Mathias CJ. Multiple system atrophy and autonomic failure. J Neural Transm Suppl 2006; 70: 343-347
    PubMedGoogle Scholar
  • 10 Benarroch EE, Schmeichel AM, Sandroni P et al. Differential involvement of hypothalamic vasopressin neurons in multiple system atrophy. Brain 2006; 129: 2688-2696
    CrossrefPubMedGoogle Scholar
  • 11 Kao AW, Racine CA, Quitania LC et al. Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer disease and associated disorders 2009; 23: 365-370
    CrossrefPubMedGoogle Scholar
  • 12 Balas M, Balash Y, Giladi N et al. Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. J Neural Transm 2010; 117: 369-375
    CrossrefPubMedGoogle Scholar
  • 13 Lipp A, Sandroni P, Low PA. Systemic postganglionic adrenergic studies do not distinguish parkinson’s disease from multiple system atrophy. Journal of the neurological sciences 2009; 281: 15-19
    CrossrefPubMedGoogle Scholar
  • 14 Wenning GK, Stefanova N, Jellinger KA et al. Multiple system atrophy: a primary oligodendrogliopathy. Annals of neurology 2008; 64: 239-246
    CrossrefPubMedGoogle Scholar
  • 15 Quinn N. Multiple system atrophy – the nature of the beast. J Neurol Neurosurg Psychiatry 1989; Suppl: 78-89
    PubMedGoogle Scholar
  • 16 Seppi K, Schocke MF, Mair KJ et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuro Image 2006; 31: 240-245
    PubMedGoogle Scholar
  • 17 Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24: 949-964
    CrossrefPubMedGoogle Scholar
  • 18 Kollensperger M, Seppi K, Liener C et al. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771-1776
    CrossrefPubMedGoogle Scholar
  • 19 Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI. Der Nervenarzt 2010; 81: 1168-1179
    CrossrefPubMedGoogle Scholar
  • 20 Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. J Neural Transm 2005; 112: 1647-1655
    CrossrefPubMedGoogle Scholar
  • 21 Wenning GK, Ben ShlomoY, Magalhaes M et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117: 835-845
    CrossrefPubMedGoogle Scholar
  • 22 Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005; 20 (Suppl. 12) S67-S76
    CrossrefPubMedGoogle Scholar
  • 23 Wenning GK, Colosimo C, Geser F et al. Multiple system atrophy. Lancet neurology 2004; 3: 93-103
    CrossrefPubMedGoogle Scholar
  • 24 Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737-745
    CrossrefPubMedGoogle Scholar
  • 25 Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. The Journal of urology 1994; 151: 1336-1341
    PubMedGoogle Scholar
  • 26 Stefanova N, Tison F, Reindl M et al. Animal models of multiple system atrophy. Trends in neurosciences 2005; 28: 501-506
    CrossrefPubMedGoogle Scholar
  • 27 Holmberg B, Johansson JO, Poewe W et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007; 22: 1138-1144
    CrossrefPubMedGoogle Scholar
  • 28 Dodel R, Spottke A, Gerhard A et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25: 97-107
    CrossrefPubMedGoogle Scholar
  • 29 Bensimon G, Ludolph A, Agid Y et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132: 156-171
    PubMedGoogle Scholar
  • 30 Lee PH, Kim JW, Bang OY et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clinical pharmacology and therapeutics 2008; 83: 723-730
    PubMedGoogle Scholar
  • 31 Quinn N, Barker RA, Wenning GK. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. Clinical pharmacology and therapeutics 2008; 83: 663-665
    PubMedGoogle Scholar
  • 32 Mathias CJ, Senard JM, Braune S et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001; 11: 235-242
    CrossrefPubMedGoogle Scholar
  • 33 Vidailhet M, Rivaud S, Gouider-Khouja N et al. Eye movements in parkinsonian syndromes. Annals of neurology 1994; 35: 420-426
    CrossrefPubMedGoogle Scholar
  • 34 Litvan I, Agid Y, Jankovic J et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996; 46: 922-930
    CrossrefPubMedGoogle Scholar
  • 35 Williams DR, de Silva R, Paviour DC et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-1258
    CrossrefPubMedGoogle Scholar
  • 36 Williams DR, Holton JL, Strand K et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235-2241
    CrossrefPubMedGoogle Scholar
  • 37 Ling H, O’Sullivan SS, Holton JL et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133: 2045-2057
    PubMedGoogle Scholar
  • 38 Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9
    CrossrefPubMedGoogle Scholar
  • 39 Stamelou M, Reuss A, Pilatus U et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-949
    CrossrefPubMedGoogle Scholar
  • 40 Stamelou M, de Silva R, Arias-Carrion O et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133: 1578-1590
    CrossrefPubMedGoogle Scholar
  • 41 Di Maria E, Tabaton M, Vigo T et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Annals of neurology 2000; 47: 374-377
    CrossrefPubMedGoogle Scholar
  • 42 Wenning GK, Litvan I, Jankovic J et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. Journal of neurology, neurosurgery, and psychiatry 1998; 64: 184-189
    CrossrefPubMedGoogle Scholar
  • 43 Litvan I, Grimes DA, Lang AE. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Advances in neurology 2000; 82: 183-196
    PubMedGoogle Scholar
  • 44 Kompoliti K, Goetz CG, Boeve BF et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Archives of neurology 1998; 55: 957-961
    CrossrefPubMedGoogle Scholar
  • 45 Boeve BF, Josephs KA, Drubach DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol 2008; 89: 533-548
    PubMedGoogle Scholar
  • 46 Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. Clin Neurosci 2010; 17: 385-386
    CrossrefPubMedGoogle Scholar
  • 47 Takatsu H, Nagashirna K, Murase M et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000; 284: 44-45
    CrossrefPubMedGoogle Scholar
  • 48 Juh R, Pae CU, Kim TS et al. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005; 383: 22-27
    CrossrefPubMedGoogle Scholar
  • 49 Köllensperger M, Geser F, Seppi K et al. Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093-1099
    CrossrefPubMedGoogle Scholar
  • 50 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogenous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359
    CrossrefPubMedGoogle Scholar
  • 51 Wenning GK, Ben-Shlomo Y, Hughes A et al. . What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000; 68: 434-440
    CrossrefPubMedGoogle Scholar
  • 52 Wenning GK, Tison F, Ben-Shlomo Y et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133-147
    CrossrefPubMedGoogle Scholar